Mr. Fukushima is the incumbent Director of the Translational Research Center for Medical Innovation (TRI) in Kobe, Japan. Currently, TRI has experts that specialize in all aspects of medical innovation. Its staffing includes statisticians, mathematicians, system engineers, etc. It has also established a secretariat dedicated to cooperation and exchanges between TRI, Europe, America, and China.

It is reported that TRI has just obtained the certification of data center promoted by the European Clinical Trials Register. Mr. Fukushima said that TRI was also working to strengthen cooperation with China, South Korea, Singapore, and the United States to achieve the goal of sharing data worldwide. .

According to him, TRI has previously completed the first round of research programs on regenerative medicine, including those on nerve regeneration, vascular regeneration, cartilage regeneration, tympanic regeneration, corneal regeneration, and cardiac regeneration. “These are our most significant research achievements. Medicines for both regeneration and tympanic membrane regeneration have been approved and published on Nature Outline and are now well known around the world. We are currently conducting the second round of R&D of regenerative medicine." Mr. Fukushima said.

He also mentioned the joint research program of TRI and Fudan University to overcome Alzheimer's disease, especially MCI, was a world-class research project with unparalleled significance.

Regarding Japan's promotion of medical innovation, Mr. Fukushima believed that the current government-led allocation of funds in Japan was very effective. "To date, the Japanese academic community has developed over 90 drugs, medical equipment and regenerative medicine products, of which the government-led fund allocation is a strong driver. We also hope to share the approach of fund allocation with the world, in order to expedite global new drug R&D, and better serve patients."

At the conference, Mr. Fukushima said that he had heard a lot about China's outstanding achievements in the field of advanced medicine and new drug development. He hoped that this opportunity would generate more cooperation between China and Japan in new drug development and advanced medicine, in a bid to promote the transformation and materialization of research results. He also hoped to have more in-depth communication and cooperation with China in the medical field in the future.

Souce: BOPUZHIKU

©SCIMEA and Bopu Zhiku